Texas House Bill HB216

Texas 2025 - 89th 2nd C.S.

• Filed: 8/18/25
• Filed: 8/20/25

Summary

HB 216 would restrict how abortion-inducing drugs may be prescribed and provided in Texas. The bill requires that a physician be physically present in Texas and examine the pregnant woman in person at the time the drug is provided. In practical terms, it bars remote or out-of-state provision of abortion-inducing medication when the physician is not physically in the state and has not conducted an in-person exam at the point of dispensing. The bill also narrows existing exceptions in the Occupations Code for certain out-of-state consultation services. It preserves those exceptions generally for episodic consultation, medical school consultation, and certain institutional consultation, but makes clear that those exceptions do not apply when the consultation service involves providing an abortion-inducing drug. The bill takes effect on the 91st day after the legislative session ends.

Impact

HB 216 would amend the Health and Safety Code and the Occupations Code to impose a specific in-state, in-person requirement for the provision of abortion-inducing drugs and to limit the use of certain cross-border consultation exceptions in that context. It would affect physicians, telemedicine or remote consultation arrangements, and patients seeking medication abortion, while reinforcing state regulation of abortion-related medical practice.

Sentiment

No committee transcripts or recorded votes were provided, so there is no direct evidence of legislative debate or vote sentiment in the supplied materials. Based on the bill text alone, the measure appears to reflect a restrictive approach to abortion medication access and would likely be supported by lawmakers favoring tighter abortion regulation and opposed by those favoring broader access to reproductive healthcare.

Contention

The main point of contention is likely the requirement that a physician be physically present in Texas and conduct an in-person examination before providing an abortion-inducing drug. Supporters would view this as a patient-safety and regulatory safeguard, while opponents would likely argue that it restricts access to medication abortion, undermines telemedicine, and imposes burdens on patients in rural or underserved areas. A second area of contention is the bill’s explicit override of certain consultation exceptions when abortion-inducing drugs are involved, which limits out-of-state physician involvement in this area.